ValuEngine upgraded shares of Bio Blast Pharma (NASDAQ:ORPN) from a strong sell rating to a sell rating in a research note released on Friday.
Bio Blast Pharma (NASDAQ:ORPN) traded down $0.01 on Friday, hitting $2.21. 103,200 shares of the stock traded hands, compared to its average volume of 32,916. Bio Blast Pharma has a twelve month low of $1.49 and a twelve month high of $7.75.
A hedge fund recently raised its stake in Bio Blast Pharma stock. Renaissance Technologies LLC increased its stake in shares of Bio Blast Pharma Ltd. (NASDAQ:ORPN) by 34.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 159,300 shares of the biopharmaceutical company’s stock after purchasing an additional 40,400 shares during the quarter. Renaissance Technologies LLC owned about 0.97% of Bio Blast Pharma worth $121,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.82% of the company’s stock.
WARNING: This article was originally published by Week Herald and is owned by of Week Herald. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://weekherald.com/2017/12/04/bio-blast-pharma-orpn-upgraded-at-valuengine.html.
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bio Blast Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio Blast Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.